Physician profile
Stephen W Stripling
NPI 1538122205
$30,651.96
in general payments reported to CMS, 2019-2025
34 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,768 · 2020: $4,057 · 2021: $5,614 · 2022: $4,296 · 2023: $469 · 2024: $2,000 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Food and Beverage: $1,404 · Travel and Lodging: $830 · Gift: $117 · Long Term Medical Supply Or Device Loan: $15.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,550.00 |
| Food and Beverage | $1,403.55 |
| Travel and Lodging | $830.44 |
| Gift | $116.75 |
| Long Term Medical Supply Or Device Loan | $15.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,209.16 | 2019-2025 | |
| Lnhc, INC | $11,724.03 | 2024-2025 | Zelsuvmi |
| Sanofi Pasteur INC. | $2,845.42 | 2020-2024 | |
| Corium, LLC | $2,030.23 | 2021-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $499.93 | 2021-2025 | Qelbree, Qelbree |
| Welch Allyn | $186.14 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $180.34 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $153.90 | 2019-2025 | Dyanavel Xr |
| Baxter Healthcare | $149.82 | 2022-2024 | Hillrom - Spot Vision Screener |
| Merck Sharp & Dohme LLC | $93.39 | 2024-2025 | Gardasil 9, Gardasil, Rotateq |
| Shire North American Group INC | $75.63 | 2019 | |
| Modernatx, INC. | $64.02 | 2023 | Moderna Covid-19 Vaccine |
| Collegium Pharmaceutical, INC. | $63.23 | 2025 | Jornay Pm |
| Seqirus USA INC | $58.36 | 2022-2024 | Flucelvax |
| Ultragenyx Pharmaceutical INC. | $44.01 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $42.21 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $41.18 | 2024 | |
| Kaleo, INC. | $29.14 | 2022 | |
| Glaxosmithkline, LLC. | $26.80 | 2023-2024 | Bexsero, Pediarix |
| Sanofi-Aventis U.S. LLC | $25.27 | 2025 | |
| Nestle Healthcare Nutrition INC. | $23.20 | 2023 | |
| Qol Medical, LLC | $21.77 | 2021 | |
| Verrica Pharmaceuticals INC. | $18.27 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $16.67 | 2021 | |
| Adlon Therapeutics L.P. | $15.20 | 2021 | |
| Genentech USA, INC. | $14.64 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stripling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.